National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Liver (Hepatocellular) Cancer Screening (PDQ®)
Patient Version   Health Professional Version   Last Modified: 04/03/2008



Purpose of This PDQ Summary






Summary of Evidence






Significance






Evidence of Benefit






Evidence of Harms






Get More Information From NCI






Changes To This Summary (04/03/2008)






Questions or Comments About This Summary






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Summary of Evidence

Benefits
Harms

Note: Separate PDQ summaries on Adult Primary Liver Cancer Treatment and Childhood Liver Cancer Treatment are also available.

Benefits

Based on fair evidence, screening would not result in a decrease in mortality from hepatocellular cancer.

Magnitude of Effect: No reduction in mortality.

Study Design: Randomized controlled trials.
Internal Validity: Fair.
Consistency: Multiple studies, large number of participants.
External Validity: Fair.
Harms

Based on fair evidence, screening would result in rare but serious side effects associated with needle aspiration cytology such as needle-track seeding, particularly of lesions more than 2 cm in diameter, and hemorrhage, bile peritonitis, and pneumothorax. Transjugular liver biopsy is rarely associated with major complications such as perforation of the hepatic capsule or cholangitis.

Magnitude of Effect: Good evidence for uncommon but serious harms.

Study Design: Randomized controlled trials and observational studies.
Internal Validity: Fair.
Consistency: Multiple studies, large number of participants.
External Validity: Good.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov